论文部分内容阅读
目的探讨他汀强化联合扩容治疗对脑梗死的疗效。方法 120例新发脑梗死患者,随机分为对照组与治疗组,每组60例。对照组予以双抗治疗,治疗组予以双抗+他汀强化+扩容治疗,其余均予以活血、脑保护等治疗。治疗7 d,随访1个月,记录不良反应情况,比较两组治疗前后美国国立卫生研究院卒中量表(NIHSS)评分和日常生活能力量表(ADL)评分。结果 120例患者中有10例出现消化系统不良症状,如上腹部不适、恶心、纳差,加保护胃黏膜治疗缓解,治疗组中有3例输液过程中有胸闷心悸,减慢低速后症状缓解,1例出现皮疹而退出。治疗前两组NIHSS、ADL评分比较差异无统计学意义(P>0.05);治疗组治疗后7 d、1个月NIHSS、ADL评分均优于对照组,差异均具有统计学意义(P<0.05)。结论他汀强化联合扩容治疗可减少脑梗死的进展加重,并能显著改善脑梗死的近期和远期预后。
Objective To investigate the effect of statin intensified combined dilatation on cerebral infarction. Methods One hundred and twenty patients with newly diagnosed cerebral infarction were randomly divided into control group and treatment group, 60 cases in each group. The control group was double-anti-treatment, the treatment group was double anti-statin + dilatation therapy, the rest were given to blood circulation, brain protection and other treatment. After 7 days of treatment, the patients were followed up for 1 month. Adverse reactions were recorded. NIHSS and ADL scores were compared between the two groups before and after treatment. Results In 120 patients, 10 patients had adverse symptoms of digestive system, such as discomfort, nausea and anorexia in upper abdomen, alleviation of gastric mucosa in the upper abdomen, chest tightness and palpitation in 3 infants in the treatment group, alleviation of symptoms after low speed, 1 case of rash and exit. There was no significant difference in NIHSS and ADL score between the two groups before treatment (P> 0.05). NIHSS and ADL scores of the treatment group were better than those of the control group on the 7th day and the 1th month after treatment (P <0.05) ). Conclusions Statin combined with dilatation and expansion therapy can reduce the progress of cerebral infarction and improve the short-term and long-term prognosis of cerebral infarction.